ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

CD19+ Cell Ratio as a Predictive Marker of Antibody Mediated Rejection in ABO Incompatible Kidney Transplantation

K. Unagami,1 R. Maenosono,2 M. Furusawa,2 Y. Kakuta,2 M. Okumi,2 H. Ishida,2 K. Tanabe,2 K. Nitta.1

1Nephrology, Tokyo Women's Medical University, Tokyo, Japan
2Urology, Tokyo Women's Medical University, Tokyo, Japan.

Meeting: 2018 American Transplant Congress

Abstract number: A99

Keywords: B cells, CD20, Immunosuppression

Session Information

Date: Saturday, June 2, 2018

Session Name: Poster Session A: Kidney Acute Antibody Mediated Rejection

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall 4EF

Related Abstracts
  • Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation.
  • CD4+/CD8+ T Cell Ratio as a Predictive Marker for Early Graft Failure in Pig to Non-Human Primate Islet Xenotransplantation with Immunosuppression.

Background: Rituximab has been suggested to deplete B cells and decrease the possibility of antibody mediated rejection (AMR) in ABO-incompatible living kidney transplantation (ABO-ILKT). We investigated the relationship between the CD19+ cell ratio among B cells and the incidence of AMR to evaluate the potential of CD19+ cells before transplantation as a predictive marker of AMR.

Method: The CD19+ cell ratio was determined in 225 ABO-ILKT recipients, and related to the incidence of AMR and adverse events within 1 year after transplantation. Independent factors associated with AMR were assessed by univariate and multivariate analysis.

Results: The date of 127 ABO-ILKT recipients were included for analysis. The baseline characteristics of patients that experienced AMR differed significantly from those in the no AMR group with respect to HLA-DR mismatch, donor specific antigen, and CD19+ cells after rituximab.

CD19+ cells ratio (after rituximab before transplantation) was identified as a potential risk factor for AMR. There was a significant difference in the AMR incidence between patients with ≥2% and <2% CD19+ cells; thus, 2% was a determined as a useful cut-off value. Cytomegalovirus viremia was detected in both group, but tends to be more frequent among patients with <2% CD19+ cells; however, the difference was not statistically significant.

Conclusion: This study suggests that the CD19+ cells count before can be a simple marker to predict AMR following ABO-ILKT. Further studies are needed in a larger number of patients and over longer periods of follow-up to confirm the efficacy of this predictive marker.

CITATION INFORMATION: Unagami K., Maenosono R., Furusawa M., Kakuta Y., Okumi M., Ishida H., Tanabe K., Nitta K. CD19+ Cell Ratio as a Predictive Marker of Antibody Mediated Rejection in ABO Incompatible Kidney Transplantation Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Unagami K, Maenosono R, Furusawa M, Kakuta Y, Okumi M, Ishida H, Tanabe K, Nitta K. CD19+ Cell Ratio as a Predictive Marker of Antibody Mediated Rejection in ABO Incompatible Kidney Transplantation [abstract]. https://atcmeetingabstracts.com/abstract/cd19-cell-ratio-as-a-predictive-marker-of-antibody-mediated-rejection-in-abo-incompatible-kidney-transplantation/. Accessed January 25, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.